OTC Markets OTCQB - Delayed Quote USD

Bioxytran, Inc. (BIXT)

0.0231 +0.0001 (+0.43%)

At close: November 6 at 4:00:00 PM EST

Bioxytran Completes Production of Two Dietary Supplements: V-LO® for Immune Health and A-SUQAR® for Healthy Blood Sugar

GlobeNewswire 20d ago

BIXT
+0.43%
Bioxytran Reports Encouraging Clinical Observations in First Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Patient Treated with PLICID, a Novel Galectin Antagonist Designed with Artificial Intelligence

GlobeNewswire 2mo ago

BIXT
+0.43%
Bioxytran Highlights New Book on Real-Time Monitoring Tissue Oxygenation Relevant to Oxygen Carrier BXT-25

GlobeNewswire 5mo ago

BIXT
+0.43%
BIOXYTRAN, INC. COMPLETES $1.2 MILLION PRIVATE PLACEMENT

GlobeNewswire 7mo ago

BIXT
+0.43%
Bioxytran Secures Attested Free Sale Certification for A-SUQAR®, Opening the Path to the UAE and Gulf Markets

GlobeNewswire 4d ago

BIXT
+0.43%
Bioxytran Leverages Artificial Super Intelligence (ASI) to Design Broad-Spectrum Antiviral and Anti-Cancer Metastasis Drugs

GlobeNewswire 3mo ago

BIXT
+0.43%
Bioxytran Announces Publication of Corporate Research Report by Globe Small Cap Research

GlobeNewswire 3mo ago

BIXT
+0.43%
Bioxytran Announces Positive Dose Optimization Results and Advances Toward Phase 3 Registrational Trial for ProLectin-M

GlobeNewswire 8mo ago

BIXT
+0.43%
Bioxytran, Inc. Reports Positive Phase 1b/2a Clinical Study Results for ProLectin-M, a Broad-Range Antiviral Drug in Mild to Moderate COVID-19

ACCESS Newswire 8mo ago

BIXT
+0.43%
Presenting on Emerging Growth Conference 88 Day 2 on December 11; Register to live stream

GlobeNewswire 10mo ago

OSRH

STKXF

IXRRD

U.S. markets closed

Bioxytran, Inc. (BIXT)

Bioxytran Completes Production of Two Dietary Supplements: V-LO® for Immune Health and A-SUQAR® for Healthy Blood Sugar

Bioxytran Reports Encouraging Clinical Observations in First Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Patient Treated with PLICID, a Novel Galectin Antagonist Designed with Artificial Intelligence

Bioxytran Highlights New Book on Real-Time Monitoring Tissue Oxygenation Relevant to Oxygen Carrier BXT-25

BIOXYTRAN, INC. COMPLETES $1.2 MILLION PRIVATE PLACEMENT

Bioxytran Secures Attested Free Sale Certification for A-SUQAR®, Opening the Path to the UAE and Gulf Markets

Bioxytran Leverages Artificial Super Intelligence (ASI) to Design Broad-Spectrum Antiviral and Anti-Cancer Metastasis Drugs

Bioxytran Announces Publication of Corporate Research Report by Globe Small Cap Research

Bioxytran Announces Positive Dose Optimization Results and Advances Toward Phase 3 Registrational Trial for ProLectin-M

Bioxytran, Inc. Reports Positive Phase 1b/2a Clinical Study Results for ProLectin-M, a Broad-Range Antiviral Drug in Mild to Moderate COVID-19

Presenting on Emerging Growth Conference 88 Day 2 on December 11; Register to live stream